AN ANALYSIS OF THE TREATMENT OF SARCOPTIC MANGE IN WOMBATS USING MACROCYCLIC LACTONES, WITH SUGGESTIONS FOR FUTURE RESEARCH
|
|
- Marcus Henry Lamb
- 5 years ago
- Views:
Transcription
1 Unusual Pet and Avian Veterinarians Annual Conference 2016 p AN ANALYSIS OF THE TREATMENT OF SARCOPTIC MANGE IN WOMBATS USING MACROCYCLIC LACTONES, WITH SUGGESTIONS FOR FUTURE RESEARCH (Anne Martin Scholarship Winner) Madeleine Rowe BSc Faculty of Veterinary and Agricultural Sciences The University of Melbourne INTRODUCTION Sarcoptic mange is a major infectious disease affecting the bare- nosed wombat (Vombatus ursinus) (Skerrat et al., 1998) and a growing threat to the southern hairy- nosed wombat (Lasiorhinus latifrons; SHNW) (Ruykys et al.,2013) In high density populations, the disease can spread rapidly, resulting in epizootics and local extirpations due to reduced reproduction and increased mortalities.(hartley and English, 2005; Martin et al., 1998; Skerrat et al., 1998). The disease is caused by the Sarcoptes scabiei var. wombati mite (S. wombati) and infection manifests as a debilitating dermatological condition that causes death secondary to dehydration, starvation and bacterial infection (Triggs, 1988). The welfare implications have incited both scientists and community groups (an example of the latter being Mange Management Inc.) to investigate treatment and control options. The available treatment regimens utilising macrocyclic lactones described in the literature and currently used in the field are evaluated within this report and directions for future research are discussed. TREATMENTS Method one: Multiple injections of macrocyclic lactones Study one - A study involving captive bare- nosed wombats (Skerratt, 2003) 7 3 x 300µg/kg subcutaneous ivermectin every 10 days. Injectable long- acting procaine penicillin (15mg/kg) and benzathiane penicillin (11mg/kg) delivered with the first ivermectin injection. Outcome: Three subcutaneous injections of ivermectin eliminated clinical signs of sarcoptic mange in all wombats (N=7), however, a second course of treatment was required for complete elimination of infection in the worst affected wombats (N=3). Discussion: This study demonstrated the efficacy of ivermectin injections as a treatment for sarcoptic mange, but it is not without limitations. The effectiveness of the ivermectin injections was determined by visual observation of the resolution of the clinical signs of mange, which does not determine whether the treatments eliminated infestation or simply reduced the parasite burden to sub- clinical levels. A recrudescence of mild sarcoptic mange occurred in three wombats two months after the first course of treatment, although it is speculated that this may have been due to re- infection from mites persisting in the environment. The entire treatment protocol was repeated for these three wombats, and they were considered free of infection when they failed to show signs of mange four months after treatment ceased. These wombats also had the heaviest level of infection prior to treatment, which suggests that wombats with a heavier level of infection either shed more mites into the environment or require a 1
2 more intensive treatment regimen than wombats with mild infections to eliminate S. wombati. Further research is recommended before drawing conclusions, as this was a small- scale study (N=7). Study two - A study involving free- living bare- nosed wombats (Skerratt et al., 2004) 8 (1) 400µg/kg subcutaneous ivermectin 100 days following experimental infection of wild wombats with S. wombati (N=5). (2) 800µg/kg subcutaneous ivermectin and topical amitraz wash 128 days post- infection in wombats with unresolved infestations (N=2). (3) 2 x 800µg/kg subcutaneous ivermectin every 10 days in a single wombat (N=1) whose mange failed to resolve after (2). Outcome: A single injection of ivermectin (400µg/kg) eliminated infection in mildly affected wombats (N=2), while moderately infected wombats (N=3) required up to four more injections of ivermectin (800µg/kg) used in combination with topical amitraz for complete elimination of infection, as determined by negative skin scrapings. Discussion: This study indicated that wombats with mild mange infections may be cured while living in the wild, in spite of the potential for environmental re- exposure, and suggests that wombats do not necessarily spread mange to unaffected wombats when mildly infected. One hundred days following the initial infection of wild wombats with mites, 34 wombats that had shared burrows with the infected wombats were trapped and evaluated for signs of mange. These wombats lacked clinical signs of mange and returned negative skin scrapings. Inherent immunity to S. wombati infection in the wombat colony selected for this study is a possible explanation of these findings. Past exposure of the study group to S. wombati was unknown, although the authors remark that there may have been some acquired immunity in the population prior to this study. Unlike dogs and humans, it is unknown whether wombats are capable of developing resistance to reinfection with Sarcoptes and their antibody response to S. wombati has not been examined. 9 Method two: a single injection of a macrocyclic lactone Study three - A pharmacokinetics trial involving healthy SHNW s (Death et al., 2011) 10 1 x 200µg/kg subcutaneous moxidectin. Outcome: The average peak plasma moxidectin concentration (98.6ng/ml) was higher than that seen in livestock species and the average plasma elimination half- life (5.03 days) was shorter. Due to its short half- life, Death et al. hypothesised that a single subcutaneous injection of 200µg/kg macrocyclic lactone would not reliably clear a mange infection, due to re- infection from mites in the environment and eggs hatching on the animal. Discussion: The small scale of the study (N=4 wombats), coupled with the marked variation between the pharmacokinetic parameters measured between the wombats (for instance, half- lives varied from days) makes it difficult to draw conclusions about the pharmacokinetic parameters of moxidectin in wombats. Rather, the study demonstrates the great variation in the pharmacokinetics of moxidectin between SHNW s, highlighting the need for further research with a greater sample size. If these findings were replicated in a larger study, Death et al. indicated that the dosing protocol recommended by Bryant and Reiss ( mg/kg weekly of a macrocyclic lactone, until two weeks after negative skin scrapings are obtained) 11 would be the most likely regimen to maintain reasonably consistent plasma levels and reliably eliminate sarcoptic mange infections in circumstances where it is possible to repeatedly treat wombats. Study four A study involving free- living and captive wombats (Ruyskys et al., 2013) 2 1 x 200µg/kg subcutaneous ivermectin. Outcome: The treatment eliminated severe mange in captive SHNW s and mild but not severe mange in free- living wombats. Discussion: In spite of the hypothesis by Death et al. (above), a single 200µg/kg subcutaneous injection of ivermectin eliminated mild mange from free- living SHNW s and severe mange from captive wombats without immediate reinfection from the 2
3 environment. However, this outcome may be due to differences in the pharmacokinetics of ivermectin versus moxidectin in wombats. Elimination of S. wombati infection in free- living wombats was confirmed by negative skin scrapings and the absence of alopecia, parakeratosis and erythema 70 days post- treatment. These findings suggest that re- infection from the environment is not necessarily an immediate threat following treatment. Further studies that monitor a larger number of wombats for a recrudescence of clinical mange beyond 70 days post- treatment would be useful for drawing stronger conclusions, as this study was limited by a small sample size (N=5 animals). Method three: Topical moxidectin Treatment 5 - Mange Management Inc. in- field treatment regimen for bare- nosed wombats 12 (1) 12 x 500µg/kg topical moxidectin (Cydectin pour- on) every 7 days. (2) 4 x 500µg/kg topical moxidectin every 14 days, following (1). Method of delivery: Burrow flaps (an ice- cream lid with a milk lid inserted, placed over entrances to wombat burrows - see Figure 1.). Figure 1. Image of a burrow flap used to deliver mange treatments. 12 Volume delivered: Mange Management Inc. considers the average adult wombat affected by mange to be 25kg, equating to a dose of 2.5mL. However, a 4mL dose is placed in the burrow flap to account for spillage. Outcome: Unknown. No controlled clinical trials or pharmacokinetic studies into topical moxidectin have been published thus far. Discussion: Though this is a clever and innovative low cost approach to the problem of administering treatment to wombats without the need for capture, the evidence for its effectiveness is limited. The topical dosage rate (500µg/kg) has been directly extrapolated from the dose rate indicated by Cydectin pour- on for cattle and red deer 13, but there is currently no experimental evidence into its use in wombats. In 2015, mass- treatment trials were undertaken in Queensland (personal communication, Dr Julie Old), in Bents Basin in New South Wales (personal communication, Dr Tanya Leary) and in Narawnaptu National Park in Tasmania (personal communication, Dr Scott Carver) however, the results of these trials are yet to be published. Rather, wide- spread use of the treatment protocol is supported by anecdotal information obtained from wildlife carers, visual sightings and photos taken by camera traps outside of wombat burrows. Whilst burrow camera traps appear to demonstrate a decrease in the severity of infection with treatments, 14 photographs are unable to assess whether the treatments are completely eliminating mite infections or simply reducing mite burdens to sub- clinical levels. As such, wombats with a low level of infection could be re- developing clinical mange following the termination of treatments, as occurred in Skerratt s initial study. 7 Further analysis of the treatment protocol reveals that using a uniform volume (4mL) may be under- dosing for larger wombats, increasing the risk of resistance developing. 15 The current volume of drug delivered by the burrow- flaps is determined for wombats with an average weight of 25kg, however, the adult bare- nosed wombat can weigh anywhere between 22-50kg. 16 When using a pour- on, where the specific weight of the individual animal cannot be measured, animals should be dosed according to the weight of the heaviest animal in a group to reduce the speed of onset of resistance. 17,18 According to these principles, wombats should be dosed to a weight of 50kg, thus delivering 5mL of moxidectin per burrow- flap, plus an additional volume to accommodate for spillage and evaporation. While excessive dosing increases the risk of toxicity in compromised animals, 7,10 moxidectin has a high safety margin in many 3
4 species 19,20 and in the pharmacokinetics study by Death et al. there were no ill- effects documented in SHNW s following subcutaneous injection of moxidectin (200µg/kg). 10 For future use of topical moxidectin, investigating an effective dose rate for wombats may yield better results than using the suggested dose rates for cattle and red deer. Pharmacokinetic tests have demonstrated that the plasma elimination half- life of subcutaneously injected moxidectin in the SHNW (ranging from 2-9 days) is shorter and the average peak plasma concentration (98.6ng/ml) 7 is higher than values cited for cattle receiving the same treatment (14.5 days and 39.4ng/ml, respectively). 21 This may be due, in part, to the drug s lipophilic nature and the differences in body fat reserves between wombats and livestock. The levels of body fat encountered in livestock are likely to be higher than that of the wombat afflicted with mange and moxidectin will preferentially sequester in adipose tissue and be slowly released, influencing its persistence. 22 Treatment protocols extrapolated from livestock need to take these considerations into mind, and wombats with chronic mange and weight loss may require more frequent dosing. To further improve outcomes, the dermatological changes that occur in wombats with progressed mange should also be considered when determining a dosage rate for wombats. The skin over the rump of the wombat is thicker than the skin of the cow (10mm 23 vs. 6.2mm 24, respectively) and is thickened further by crusts when infected with sarcoptic mange. 7 The combination of thicker skin and lack of access to healthy dermis may decrease the extent of transdermal absorption of topical moxidectin, 25,26 thus decreasing the drug s bioavailability and efficacy in wombats with crusted mange. SUGGESTIONS FOR FURTHER RESEARCH 1. Undertake clinical and field trials to investigate the efficacy of the 12 dose topical moxidectin treatment protocol. Justification: To ensure wombats are not being delivered sub- therapeutic levels of moxidectin, thus selecting for resistance and introducing chemical residues to the environment. Also, to allow the creation of a dosage treatment baseline for further research into other topical moxidectin treatment protocols, with the view of decreasing the total number of treatments required to control infection. 2. Undertake long- term studies to determine whether wombats treated to the point of sub- clinical infection re- develop clinical signs of mange following the termination of treatments and determine under what circumstances wombats with complete elimination of infection become re- infected from their environment. Justification: To determine the value of treating free- living wombats with mange, and as such, to determine whether the focus of research should shift towards preventative mechanisms, such as developing a vaccine or identifying and propagating genetics that confer wombats greater resistance to S. wombati infections. 3. Determine the pharmacokinetic parameters and plasma drug deposition profile of topical moxidectin in wombats. Justification: To determine the minimum dose necessary for parasiticidal activity in wombats and the protocol required to maintain plasma concentrations at this level for an adequate duration. CONCLUSION Subcutaneous macrocyclic lactone injections have demonstrated efficacy at eliminating mild- severe sarcoptic mange infections in captive wombats 2,7 and mild mange in free- ranging wombats. 8 However, there is currently no proven effective treatment that eliminates moderate- severe mange in free- ranging wombats that avoids recapture. There is a clear indication to perform rigorously designed long- term clinical trials and further pharmacological studies into the pharmacodynamics of moxidectin in wombats. These trials should use objective outcomes to examine the effectiveness of topical moxidectin at eliminating sarcoptic mange from wombats and preventing its recurrence. References 1. Skerratt LF, Martin RW, Handasyde KA. Sarcoptic mange in wombats. Aus Vet J. 1998;77: Ruykys L, Breed B, Schultz D et al. Effects and treatment of sarcoptic mange in southern 4
5 hairy- nosed wombats (Lasiorhinus Latifrons). J Wildl Dis. 2013;49: Hartley M, English A. Sarcoptes scabiei var. wombati infection in the common wombat (Vombatus ursinus). Eur J Wildl Res. 2005;51: Martin RW, Handasyde KL, Skerratt LF. Current Distribution of sarcoptic mange in wombats. Aus Vet J. 1998;77: Skerratt LF, Martin RW, Handasyde KA. Sarcoptic mange in wombats. Aus Vet J. 1998;77: Triggs B. The Wombat; Common Wombats in Australia. New South Wales University Press, Kensington, Skerratt LF. Clinical response of captive common wombats (Vombatus ursinus) infected with sarcoptes scabiei var. wombati. J Wildl Dis. 2003;39: Skerratt LF, Skerratt HL, Martin R et al. The effects of sarcoptic mange on the behaviour of wild common wombats (Vombatus ursinus). Aust J Zool. 2004;52: Emery D. Host- parasite relationships, pathophysiologic & immunity. In: Beveridge I, Emery D. Australasian Animal Parasites: Inside and Out. The Australian Society for Parasitology Inc, 2015: Death CE, Taggart DA, Williams DB et al. Pharmacokinetics of moxidectin in the southern hairy- nosed wombat (Lasiorhinus Latifrons). J Wildl Diseases. 2011;47: Vogelnest L, Woods R. Medicine of Australian Mammals. CSIRO Publishing, Collingwood, Treatment Methods. methods/. Retrieved 12 May Cydectin pour- on for cattle and red deer: Quick reference guide. producers/beef/products/drenches- broad- spectrum/cydectin- pour- on.html. Retrieved 10 May Success stories. stories/. Retrieved 10 June FDA s public meeting on antiparasitic drug use and resistance in ruminants and equines an overview. ary/resourcesforyou/ucm pdf - pg 16. Retrieved 27 July Jackson S. Australian Mammals: Biology and Captive Management. CSIRO publishing, Collingwood, Levot G. Off- shears backline treatment. Off_shears_backline_treatments.pdf. Retrieved 28 July Love S. Wormkill the basics. data/assets/pdf _file/0007/365956/wormkill- the- basics.pdf. Retrieved 28 July Virbac (Australia) Pty Limited. Cydectin Pour- On for Cattle and Red Deer. public/files/pdf/sds/livestock/cydectinpouron- SDS.pdf May Food and Drug Administration. ProHeart 6 (moxidectin). Fort Dodge Animal Health. mittees/committeesmeetingmaterials/veterina rymedicineadvisorycommittee/ucm pd f. January Retrieved April Lanusse C, Lifschitz A, Virkel G et al. Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. J Vet Pharmacol Ther. 1997;20: Craven J, Bjorn H, Hennessy DR et al. The effects of body composition on the pharmacokinetics of subcutaneously injected ivermectin and moxidectin in pigs. J Vet Pharmacol Ther. 2002;25: Woodford R. The secret life of wombats. Text Publishing, Melbourne, Dowling DF. The thickness of cattle skin. Aust J Agric Res. 1955;5: Grasso P, Lansdown ABG. Methods of measuring, and factors affecting, percutaneous absorption. J Soc Cosmet Chem. 1972;23: Nair A, Jacob, Al- Dhubiab B et al. Basic considerations in the dermatokinetics of topical formulations. Braz J Pharm Sci. 2013;49:
PHARMACOKINETICS OF MOXIDECTIN IN THE SOUTHERN HAIRY-NOSED WOMBAT (LASIORHINUS LATIFRONS)
Journal of Wildlife Diseases, 47(3), 2011, pp. 643 649 # Wildlife Disease Association 2011 PHARMACOKINETICS OF MOXIDECTIN IN THE SOUTHERN HAIRY-NOSED WOMBAT (LASIORHINUS LATIFRONS) Clare E. Death, 1,5,6
More informationCOMMON MANGE IN DOGS AND CATS days spent on the dog Females burrow tunnels in the stratum corneum to lay eggs
COMMON MANGE IN DOGS AND CATS Sarcoptic Mange LIFE CYCLE OF Sarcoptes scabiei 17 21 days spent on the dog Females burrow tunnels in the stratum corneum to lay eggs CLINICAL SIGNS Intense pruritus Papular
More informationCydectin. Fort Dodge PRODUCT DESCRIPTION
Cydectin Fort Dodge moxidectin Injectable Solution for Beef and Nonlactating Dairy Cattle Antiparasitic Contains 10 mg moxidectin/ml Not for use in female dairy cattle of breeding age, veal calves, and
More informationStudy of Control Against Mange Mite (Sarcoptes scabiei) in Naturally Infested Rabbits in Sohag Governorate, Egypt
Research Journal of Agriculture and Environmental Management. Vol. 3(7), pp. 315-319, July, 2014 Available online at http://www.apexjournal.org ISSN 2315-8719 2014 Apex Journal International Full Length
More informationMURDOCH RESEARCH REPOSITORY
MURDOCH RESEARCH REPOSITORY This is the author s final version of the work, as accepted for publication following peer review but without the publisher s layout or pagination. The definitive version is
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT IVOMEC Injection for Pigs 10 mg/ml 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substance: Ivermectin
More informationEXCEDE Sterile Suspension
VIAL LABEL MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY EXCEDE Sterile Suspension 200 mg/ml CEFTIOFUR as Ceftiofur Crystalline Free
More informationThe treatment of sarcoptic mange in wildlife: a systematic review
https://doi.org/10.1186/s13071-019-3340-z Parasites & Vectors REVIEW Open Access The treatment of sarcoptic mange in wildlife: a systematic review Madeleine L. Rowe 1*, Pam L. Whiteley 1 and Scott Carver
More informationSheep Scab. Fig. 1: Sheep scab can be introduced from stray sheep - this perimeter fence is not secure.
Sheep Scab Phil Scott DVM&S, DipECBHM, CertCHP, DSHP, FRCVS Cause Sheep scab is caused by the mitepsoroptes ovis; cattle are rarely affected. Mites are most commonly transmitted by direct contact with
More informationTreating Wombats to prevent & reverse mange
Treating Wombats to prevent & reverse mange The Wombat Protection Society has been working for many years with groups and individuals to eradicate mange throughout Australia. This booklet is for people
More informationComparison of Efficacy, Side Effects, and Cost of Isoxasolines and Ivermectin Against Generalized Canine Demodicosis
Comparison of Efficacy, Side Effects, and Cost of Isoxasolines and Ivermectin Against Generalized Canine Demodicosis Item Type text; Electronic Thesis Authors Leinart, Linzey Barbara Publisher The University
More informationdiscover the nextgeneration of flea & tick protection NEW TASTY CHEW ONE CHEW ONCE A MONTH
discover the nextgeneration of flea & tick protection KILLS FLEAS KILLS TICKS ONE CHEW ONCE A MONTH TASTY CHEW NEW Now there s a new oral treatment that offers effective flea AND tick control on dogs for
More informationAdministering wormers (anthelmintics) effectively
COWS www.cattleparasites.org.uk Administering wormers (anthelmintics) effectively COWS is an industry initiative promoting sustainable control strategies for parasites in cattle Wormer administration Dec
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationFDA S ANTIPARASITIC RESISTANCE MANAGEMENT STRATEGY (ARMS)
FDA S ANTIPARASITIC RESISTANCE MANAGEMENT STRATEGY (ARMS) Michelle Kornele, DVM Anna O Brien, DVM Aimee Phillippi-Taylor, DVM, DABVP (Equine) Overview Antiparasitic resistance is an issue for grazing livestock
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cydectin 1% w/v Injectable Solution for Sheep 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Moxidectin Excipients
More informationEfficacy of Moxidectin 6-Month Injectable and Milbemycin Oxime/Lufenuron Tablets Against Naturally Acquired Toxocara canis Infections in Dogs*
Efficacy of Moxidectin 6-Month Injectable and Milbemycin Oxime/Lufenuron Tablets Against Naturally Acquired Toxocara canis Infections in Dogs* Dwight D. Bowman, MS, PhD a Walter Legg, DVM b David G. Stansfield,
More informationDosing Your Cat with Azithromycin Pediatric Suspension. By Lorraine Shelton
Dosing Your Cat with Azithromycin Pediatric Suspension By Lorraine Shelton To join a community of cat fanciers and health professionals interested in cattery related health issues, visit http://groups.yahoo.com/group/fanciershealth
More informationGET YOUR CATTLE PERFORMANCE READY WITH MULTIMIN IMPROVING FERTILITY IN BEEF CATTLE
GET YOUR CATTLE PERFORMANCE READY WITH MULTIMIN IMPROVING FERTILITY IN BEEF CATTLE IMPACT OF CALVING PATTERN UPON PROFITABLITY Heifers and cows cycle every 21 days. This means all breeding females have
More informationBaytril 100 (enrofloxacin) Injectable is FDA-approved for BRD control (metaphylaxis) in high-risk cattle.
Baytril 100 (enrofloxacin) Injectable is FDA-approved for BRD control (metaphylaxis) in high-risk cattle. Whether controlling or treating BRD, it s important to kill bacteria to let the calf s immune system
More informationAUSTRALIA S PREMIER VETERINARY SCIENCE TEXT
AUSTRALIA S PREIER VETERINARY SCIENCE TEXT CASE SERIES Outbreaks of sarcoptic mange in free-ranging koala populations in Victoria and South Australia: a case series KN Speight, a * PL Whiteley, b L Woolford,
More informationSpot-on for Dogs and Cats
NEW Spot-on for Dogs and Cats INTRODUCING NEW BRAVECTO SPOT-ON FOR DOGS AND CATS You re always looking to provide the best care for your clients and their pets. Since 2015 Bravecto Chew for Dogs has been
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationJanuary 23, 2014 Anna O Brien, DVM Veterinary Medical Officer Office of New Animal Drug Evaluation Center for Veterinary Medicine-FDA
CVM s Antiparasitic Resistance Management Strategy January 23, 2014 Anna O Brien, DVM Veterinary Medical Officer Office of New Animal Drug Evaluation Center for Veterinary Medicine-FDA Goals for this presentation
More informationUS Federal law restricts this drug to use by or on the order of a licensed veterinarian.
PFIZER INC. PFIZER ANIMAL HEALTH USA Product Label http://www.vetdepot.com 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269 833 4000 Customer Service: 800 733 5500 and 800 793 0596 Veterinary Medical
More informationDeworming: Relationships, Resistance, Refugia
Deworming: Relationships, Resistance, Refugia Drs. Sandy Stuttgen & Sarah Mills-Lloyd Agriculture Educators University of Wisconsin Extension Parasite Control Requires an Integrated Approach Clean Pastures
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationIt s Back! T echnical Manual. Fast, effective lice control for sheep
It s Back! T echnical Manual Fast, effective lice control for sheep INTRODUCTION EUREKA GOLD is an off-shears spray-on backline lice treatment indicated for the control of organophosphate (OP) susceptible
More informationThe world s first and only pour-on anti-inflammatory for cattle FAST PAIN RELIEF
The world s first and only pour-on anti-inflammatory for cattle FAST PAIN RELIEF NOTHING IS SIMPLER THAN POUR-ON RELIEF FOR PAIN, FEVER AND ACUTE INFLAMMATION easy to dose easy to apply easy on animals
More informationCydectin Pour-On for Cattle
Cydectin Pour-On for Cattle moxidectin Pour-On for Beef and Dairy Cattle Antiparasitic Contains 5 mg moxidectin/ml For Treatment of Infections and Infestations Due to Internal and External Parasites of
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12 1. NAME OF THE VETERINARY MEDICINAL PRODUCT HALOCUR 0.5 mg/ml oral solution for calves 2. Qualitative and quantitative composition Active substance Halofuginone
More informationPesky Ectoparasites. Insecta fleas, lice and flies. Acari- ticks and mites
Pesky Ectoparasites Parasite control should be at the forefront of every pet owner s life as all animals have the propensity to contract numerous ones at one stage or another. They are a challenge to the
More informationBreed differences in the pharmacokinetics of ivermectin administered subcutaneously to Holstein and Belgian Blue calves
Available online at www.sciencedirect.com Veterinary Parasitology 152 (2008) 136 140 www.elsevier.com/locate/vetpar Breed differences in the pharmacokinetics of ivermectin administered subcutaneously to
More informationParasite control in beef and dairy cattle
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Parasite control in beef and dairy cattle Author : Louise Silk Categories : Farm animal, Vets Date : August 22, 2016 Control
More informationEuropean Public MRL assessment report (EPMAR)
18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3
More informationSUMMARY OF THE PRODUCT CHARACTERISTICS
SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animec 5 mg/ml Pour-on Solution for Cattle 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance Ivermectin 5 mg/ml
More informationIn cattle: For the treatment of infections with the following parasites
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Kilo-mec 0.5 % Pour-On Solution for Cattle 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains: Active substance Ivermectin 5 mg Excipients
More informationThere s nothing like it.
THE LONGEST LASTING PROTECTION: 120 days protection against Barber s Pole Worm 112 days protection against Ostertagia (Small brown stomach worm) 51 days prevention of development of viable cattle ticks
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationUPDATE ON THE DIAGNOSIS AND MANAGEMENT OF DEMODICOSIS
UPDATE ON THE DIAGNOSIS AND MANAGEMENT OF DEMODICOSIS James O. xon, DVM, DACVIM Morrill Professor Department of Veterinary Clinical Sciences College of Veterinary Medicine Iowa State University Ames, IA
More informationSaunders Solutions in Veterinary Practice Small Animal Dermatology by Anita Patel and Peter Forsythe 2008 Elsevier Ltd. All rights reserved.
4 Sarcoptic mange INITIAL PRESENTATION Pruritus with erythema, alopecia, papules, crusting and scaling. INTRODUCTION Sarcoptic mange (also referred to as scabies) is a highly contagious, intensely pruritic
More informationSarcoptic Mange in Pigs A review. Lee McCosker. 28 th August Introduction
Sarcoptic Mange in Pigs A review Lee McCosker 28 th August 2014 Introduction Sarcoptic mange in pigs is caused by the mite Sarcoptes scabiei var. suis is and is the most important ectoparasitic disease
More informationComparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle
Treatment Study DRAXXIN vs. Nuflor July 2005 Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle Pfizer Animal Health, New York,
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/005/00-FINAL-Rev.1 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE TESTING
More informationHorse Owner s Guide To Worming
Horse Owner s Guide To Worming Bimeda Equine is proud to promote best practice targeted worming regimes, to help protect both today s horses and future generations. Bimeda Equine Proudly Promoting Responsible
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Revised: December 2011 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Dectomax 10 mg/ml Solution for Injection for Pigs (UK) Zearl 10 mg/ml Solution for Injection for Pigs
More informationLufenuron. Technical Profile
Lufenuron Technical Profile Lufenuron Virbac is proud to have the insect growth regulator (IGR) lufenuron as part of its parasiticide portfolio. Lufenuron is also referred to as an insect development inhibitor
More informationDOSE TITRATION, EFFICACY AND SAFETY OF DROP ON IVERMECTIN FOR THE MANAGEMENT OF KNEMIDOCOPTES SPP INFESTATION IN BUDGERIGARS.
676 J App Pharm 03(04): 670-675; October, 2012 Kamal et al., 2012 Original Research Article DOSE TITRATION, EFFICACY AND SAFETY OF DROP ON IVERMECTIN FOR THE MANAGEMENT OF KNEMIDOCOPTES SPP INFESTATION
More informationFarm Newsletter - August 2016
Farm Newsletter - August 2016 Back by Popular Demand MVC Social and Skittles Night Wednesday 14th September, 7:30pm The Bell, Chittlehampton (Join us for what promises to be a great night.) The last few
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationIntroducing the latest in worming technology...
Introducing the latest in worming technology... Bayer s E-MOX PRO is a new Moxidectin triple active combination oral paste that provides the complete worming solution for horses. E-MOX PRO provides broad
More informationJust where it s needed.
Relief. Just where it s needed. Tissue-selective 7,8 Strong safety profile 5,6,10,11 For dogs and cats Onsior is available in a range of convenient and easy-to-dose formulations. Injectable solution for
More informationAntibiotics use and Considerations: Calves and Heifers CLASSIFICATION OF CALVES. Danielle A. Mzyk TITLE 24 PT. ARIAL BOLD ALL CAPS
CALF AND HEIFER CONGRESS - 2016 Antibiotics use and Considerations: Calves and Heifers Danielle A. Mzyk TITLE 24 PT. ARIAL BOLD ALL CAPS Today s Presentation Classification of Calves Define Preruminant
More informationDemodectic mange (unlike sarcoptic mange) is not considered a very contagious disease and isolation of affected dogs is not considered necessary.
Demodectic Mange (Sometimes called red mange or demodicosis) The Culprit - Demodex Canis Demodectic mange, also called demodicosis, is caused by a microscopic mite. All dogs raised normally by their mothers
More informationANNEX I. Marketing Authorisation Holder (Name and address): Reference Member State:
ANNEX I LIST OF THE PHARMACEUTICAL FORMS, STRENGTHS, ROUTES OF ADMINISTRATION, PACKAGING AND PACKAGE SIZES OF THE VETERINARY MEDICINAL PRODUCT IN THE MEMBER STATES ANNEX I Marketing Authorisation Holder
More informationParasite Prevention Strategies for Bison.
Parasite Prevention Strategies for Bison Donald H. Bliss, Ph.D. Veterinary Parasitologist MidAmerica Ag Research Verona, WI drbliss@chorus.net www.midamericaagresearch.net Parasite Control is Paramount
More informationWombats, National Icon? Mange, International Disgrace
Wombats, National Icon? Mange, International Disgrace 1 My name is Amanda Cox and I am the Public Officer for the Wombat Protection Society of Australia. The Society has members from all States and members
More informationWe have two basic regimens for keeping the parasites in and on your horse to a minimum:
Equine Veterinary Associates Deworming Protocol We have two basic regimens for keeping the parasites in and on your horse to a minimum: 1. Rotational Deworming TIME FOR A CHANGE The goal of this regimen
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Chanimec 10 mg/ml solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Ivermectin
More informationEprimec. The PROVEN endectocide that increases your profits.
w w w. a g r o v e t m a r k e t. c o m Eprimec Pour on The PROVEN endectocide that increases your profits www.eprimec.com e p r i n o m e c t i n 0, 5 % EPRIMEC ZERO POUR ON EPRIMEC ZERO POUR ON is an
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995, as amended European Communities (Animal Remedies) (No. 2) Regulations 2007 VPA: 10988/081/002 Case No: 7007872 The Irish Medicines Board in exercise of the powers conferred
More informationFREEDOM OF INFORMATION SUMMARY
Date of Approval: June 30, 2004 FREEDOM OF INFORMATION SUMMARY SUPPLEMENTAL NEW ANIMAL DRUG APPLICATION NADA 141-095 (doramectin) To extend the period of persistent effect for Cooperia oncophora and Dictyocaulus
More information2012 Flystrike R & D. Technical Update. SkinTraction An intradermal alternative to mulesing
2012 Flystrike R & D Technical Update SkinTraction An intradermal alternative to mulesing Peter St Vincent Welch R&D Director Cobbett Technologies Pty Ltd The Challenge Develop an low stress method to
More informationSUMMARY OF THE PRODUCT CHARACTERISTICS
SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animec Super Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance(s):
More informationchoice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*
Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz
More informationEuropean public MRL assessment report (EPMAR)
15 January 2013 EMA/CVMP/914694/2011 Committee for Medicinal Products for Veterinary Use (CVMP) European public MRL assessment report (EPMAR) Fenbendazole (extension to chicken and extrapolation to all
More informationMastitis and On-Farm Milk Cultures - A Field Study - Part 1
Mastitis and On-Farm Milk Cultures - A Field Study - Part 1 This two-part article discusses the results of a research project undertaken by Dr. Tim Olchowy, Senior Lecturer in Livestock Medicine, School
More information- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
MERIAL LTD. USA Product Label http://www.vetdepot.com 3239 SATELLITE BLVD., DULUTH, GA, 30096 Telephone: 888-637-4251 Website: www.merial.com GASTROGARD Merial (omeprazole) Oral Paste for Equine Ulcers
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 February 2016 CVMP/344/1999-Rev.2 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in Draft Draft
More informationFor the treatment and prevention of infections caused by:
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYDECTIN 0.1 % W/V ORAL SOLUTION for sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active substance Moxidectin
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
19 January 2017 EMA/CVMP/344/1999-Rev.2 Committee for Medicinal products for Veterinary Use Guideline on the conduct of efficacy studies for intramammary products for use in cattle Draft agreed by Efficacy
More informationUPDATE ON THE ANIMAL MEDICINAL DRUG USE CLARIFICATION ACT OF 1994 REGULATIONS FOR WILDLIFE VETERINARIANS
UPDATE ON THE ANIMAL MEDICINAL DRUG USE CLARIFICATION ACT OF 1994 REGULATIONS FOR WILDLIFE VETERINARIANS Mark L. Drew, D VM Department of Large Animal Medicine and Surgery, College of Veterinary Medicine,
More informationExample 1: Quality Assurance Individual
Example 1: Quality Assurance Individual Use the available medicine labels to answer the following questions: 1 What is the name of the chemical compound in the product? 2 Is refrigeration required for
More informationFASINEX 100 Oral Flukicide for Sheep, Cattle and Goats
Date of change: 12 February 2004 Page: 1 of 12 Bottle, front panel READ SAFETY DIRECTIONS BEFORE OPENING OR USING FOR ANIMAL TREATMENT ONLY FASINEX 100 Oral Flukicide for Sheep, Cattle and Goats Active
More informationVETERINARY MEDICINAL PRODUCTS CONTROLLING VARROA JACOBSONI AND ACARAPIS WOODI PARASITOSIS IN BEES
VETERINARY MEDICINAL PRODUCTS CONTROLLING VARROA JACOBSONI AND ACARAPIS WOODI PARASITOSIS IN BEES Guideline Title Veterinary Medicinal Products controlling Varroa jacobsoni and Acarapis woodi parasitosis
More informationAntimicrobial Stewardship and Use Monitoring Michael D. Apley, DVM, PhD, DACVCP Kansas State University, Manhattan, KS
Antimicrobial Stewardship and Use Monitoring Michael D. Apley, DVM, PhD, DACVCP Kansas State University, Manhattan, KS Defining antimicrobial stewardship is pivotal to our ability as veterinarians to continue
More informationDairy goat farming in Australia: current challenges and future developments
Dairy goat farming in Australia: current challenges and future developments Pietro Celi (DVM, PhD) & Peter White (BVSc, PhD) Faculty of Veterinary Science, University of Sydney 1 Feral Goats 2 Meat Goats
More informationNew treatments for psoriasis: which biologic is best? Nelson A A, Pearce D J, Fleischer A B, Balkrishnan R, Feldman S R
New treatments for psoriasis: which biologic is best? Nelson A A, Pearce D J, Fleischer A B, Balkrishnan R, Feldman S R Record Status This is a critical abstract of an economic evaluation that meets the
More informationDemodex in Puppies. Demodectic mange looks like hair loss in small dime to quarter shapes on the face and forelegs.
Demodex in Puppies Demodectic mange looks like hair loss in small dime to quarter shapes on the face and forelegs. There is a big difference between Localized and Generalized Demodex. Demodectic mange
More informationINTRODUCTION TO WILDLIFE PHARMACOLOGY. Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre
INTRODUCTION TO WILDLIFE PHARMACOLOGY Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre General Pharmacology Factors That Affect Drug Absorption The dosage form Blood supply to the area
More informationEconomic Significance of Fasciola Hepatica Infestation of Beef Cattle a Definition Study based on Field Trial and Grazier Questionnaire
Economic Significance of Fasciola Hepatica Infestation of Beef Cattle a Definition Study based on Field Trial and Grazier Questionnaire B. F. Chick Colin Blumer District Veterinary Laboratory, Private
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationHUSK, LUNGWORMS AND CATTLE
Vet Times The website for the veterinary profession https://www.vettimes.co.uk HUSK, LUNGWORMS AND CATTLE Author : Alastair Hayton Categories : Vets Date : July 20, 2009 Alastair Hayton discusses how best
More informationGUIDELINES ON CHOOSING THE CORRECT ERADICATION TECHNIQUE
GUIDELINES ON CHOOSING THE CORRECT ERADICATION TECHNIQUE PURPOSE... 2 1. RODENTS... 2 1.1 METHOD PROS AND CONS... 3 1.1. COMPARISON BETWEEN BROUDIFACOUM AND DIPHACINONE... 4 1.2. DISCUSSION ON OTHER POSSIBLE
More informationAustralian and New Zealand College of Veterinary Scientists. Fellowship Examination. Veterinary Anaesthesia and Critical Care Paper 1
Australian and New Zealand College of Veterinary Scientists Fellowship Examination June 2016 Veterinary Anaesthesia and Critical Care Paper 1 Perusal time: Twenty (20) minutes Time allowed: Three (3) hours
More informationFluralaner (mg) for small cats kg for medium-sized cats > kg for large cats > kg 1.
1. NAME OF THE VETERINARY MEDICINAL PRODUCT Bravecto 112.5 mg spot-on solution for small cats (1.2 2.8 kg) Bravecto 250 mg spot-on solution for medium-sized cats (>2.8 6.25 kg) Bravecto 500 mg spot-on
More informationDP.1. Control tables
Data inclusion criteria Report year: 2015 Country: Croatia EU Submission: ALL Genetic status: ALL Animal Species: ALL Species grouping Level 1: ALL Species grouping Level 2: ALL Mammals: ALL Non-human
More informationDP.1. Control tables
Data inclusion criteria Report year: 2014 Country: Croatia EU Submission: ALL Genetic status: ALL Animal Species: ALL Species grouping Level 1: ALL Species grouping Level 2: ALL Mammals: ALL Non-human
More informationFinal Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014
Final Report Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014 PUBLISHED BY Meat & Livestock Australia Limited Locked Bag 991 NORTH SYDNEY NSW 2059
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Prinovox 250 mg + 62.5 mg spot-on solution for large dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2.5 ml pipette
More information206 Adopted: 4 April 1984
OECD GUIDELINE FOR TESTING OF CHEMICALS 206 Adopted: 4 April 1984 1. I N T R O D U C T O R Y I N F O R M A T I O N P r e r e q u i s i t e s Water solubility Vapour pressure Avian dietary LC50 (See Test
More informationSUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationThe Impact of Translactational Delivered Meloxicam Analgesia on Biomarkers of Pain and Distress after Piglet Processing
Animal Industry Report AS 660 ASL R2836 2014 The Impact of Translactational Delivered Meloxicam Analgesia on Biomarkers of Pain and Distress after Piglet Processing Jessica L. Bates Iowa State University,
More informationPlease refer to Table 1 Dosage and Treatment Schedule TABLE 1 Species Product Number of Tubes Cats. Rabbits or Advantage 40 for Cats
Advantage Introduction Company name: Bayer plc Address: Animal Health Division Bayer House, Strawberry Hill, Newbury Berkshire RG14 1JA Telephone: 01635 563000 Fax: 01635 563622 Email: animal.health@bayerhealthcare.com
More informationSINGLE ANNUAL IMPLANT
Manage pet ferret adrenal cortical disease with a SINGLE ANNUAL IMPLANT NOT APPROVED BY FDA Legally marketed as an FDA Indexed Product under MIF 900-013. FOR USE IN FERRETS ONLY. Extra-label use is prohibited.
More informationFLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER
FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER 1. NAME OF THE VETERINARY MEDICINAL PRODUCT FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance:
More informationANTICOCCIDIALS USED FOR THE THERAPY OF COCCIDIOSIS IN CHICKENS, TURKEYS AND GEESE
ANTICOCCIDIALS USED FOR THE THERAPY OF COCCIDIOSIS IN CHICKENS, TURKEYS AND GEESE Guideline Title Anticoccidials used for the Therapy of Coccidiosis i n Chickens, Turkey and Geese Legislative Basis Directive
More information